authors
- Spreafico, Anna
- Chi, Kim N
- Sridhar, Srikala S
- Smith, David C
- Carducci, Michael Anthony
- Kavsak, Peter
- Wong, Tracy S
- Wang, Lisa
- Ivy, S Percy
- Mukherjee, Som
- Kollmannsberger, Christian K
- Hotte, Sebastien
A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- May 20, 2013
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal